USD 44 Bn Medical Foods Market to Grow at a CAGR of 7.5% During 2023 to 2031 | Transparency Market Research
29 mars 2023 15h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, March 30, 2023 (GLOBE NEWSWIRE) -- According to market research conducted by TMR, the global medical foods industry was valued at USD 23.0 Bn in 2022 and is...
AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH
07 mars 2023 03h00 HE
|
AB2 Bio Ltd
Topline pivotal Phase 3 results expected during second half of 2023Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne...
Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD
06 mars 2023 08h30 HE
|
Novelmed Therapeutics Inc
---Single therapy for multiple forms of Age-Related Macular Degeneration (AMD) NM3086 is a highly potent Alternative Pathway (AP) blocker that does not affect the Classical Pathway (CP).Dysfunction...
Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Clinical Trial in Naïve aHUS Patients (Rare Disease)
30 janv. 2023 08h30 HE
|
Novelmed Therapeutics Inc
-- FDA Clears Initiation of Efficacy Trial in aHUS (Atypical Hemolytic Uremic Syndrome) Patients An Efficacy Trial in Adult aHUS Patients Who Are Naïve to Complement Inhibitor Therapy...
Dutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital Hyperinsulinism
21 avr. 2022 02h00 HE
|
Xinvento BV
AMSTERDAM, April 21, 2022 (GLOBE NEWSWIRE) -- Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces today the completion of a seed funding...
Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
06 déc. 2021 07h00 HE
|
Amydis, Inc.
SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a biotechnology company developing novel ocular contrast agents (“tracers”) targeting CNS biomarkers in the eye, today announced the...
Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak
27 avr. 2020 13h00 HE
|
FFF Enterprises.com
Temecula, April 27, 2020 (GLOBE NEWSWIRE) -- FFF Enterprises and BioNews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help...
AB Science annonce que la FDA autorise le recrutement de patients aux USA dans l’étude de phase 3 du masitinib dans la Sclérose Latérale Amyotrophique (SLA)
31 mars 2020 11h35 HE
|
AB Science
Paris, 31 mars 2020, 17h30 La FDA autorise le recrutement de patients aux USA dans l’étude dephase 3 du masitinib dans la Sclérose Latérale Amyotrophique (SLA) AB Science SA (NYSE Euronext –...
AB Science announces that FDA clears masitinib IND in Amyotrophic Lateral Sclerosis (ALS), allowing U.S. patient enrollment to commence in Phase 3 study
31 mars 2020 11h35 HE
|
AB Science
Paris, March 31, 2020, 5.30pm FDA clears masitinib IND in Amyotrophic Lateral Sclerosis (ALS), allowing U.S. patient enrollment to commence in Phase 3 study AB Science SA (NYSE Euronext -...
AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
23 déc. 2019 02h11 HE
|
AB Science
Paris, 23 December 2019, 8.15am New results published in the peer-reviewed journal Gliafurther support masitinib’s potential mode of action in ALS AB Science SA (NYSE Euronext - FR0010557264 - AB)...